Clinical Trial Update: Aleniglipron Phase 2 in Type 2 Diabetes Mellitus [Phase 2]

View source ↗

Summary

Aleniglipron Phase 2 trial for obesity and type 2 diabetes mellitus is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• Aleniglipron (GSBR-1290)

Snippet

Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Conditions: Obese, Obesity | Phase 2 | Status: RECRUITING